Critical appraisal on the use of everolimus in renal transplantation as an immunosuppressant to prevent organ transplant rejection

Review

(2304) Views  (1128) Full article downloads

Authors: Fernando Giron, Yenny Baez

Published Date January 2010 Volume 2010:2 Pages 11 - 14

DOI: http://dx.doi.org/10.2147/TRRM.S5135

Fernando Giron, Yenny Baez

Kidney Transplant Service, Colombiana de Trasplantes, Bogota, Colombia

Abstract: Everolimus is a proliferation inhibitor designed to target chronic allograft nephropathy including prevention of acute rejection. Acute renal allograft rejection incidence varies with the therapy used for immunosuppression. Registry data show that 15% to 35% of kidney recipients will undergo treatment for at least one episode of acute rejection within the first post-transplant year. Everolimus has been used as therapy with full- or reduced-dose cyclosporine A without evidence of increasing the acute rejection incidence. This review will summarize the available clinical trial data on the use of everolimus and its role in preventing acute rejection incidence in renal transplantation.

Keywords: calcineurin inhibitors, cyclosporine, everolimus, biopsy-proven acute rejection, renal transplantation, acute rejection